Advertisment

Revvity, Inc.: Unveiling New Brand and Showcasing Life Sciences Innovations at SLAS2024

author-image
Ethan Sulliva
New Update
NULL

Revvity, Inc.: Unveiling New Brand and Showcasing Life Sciences Innovations at SLAS2024

Advertisment

Revvity, Inc., a trailblazer in the life sciences and diagnostics industry, is ready to present its new branding and a selection of more than 40 products at the Society for Laboratory Automation and Screening (SLAS2024) in Boston. With a revenue of over $2.7 billion and a workforce of more than 11,000 dedicated employees, Revvity is committed to expanding human potential through science.

Advertisment

Commitment to Innovation and Human Health

Revvity's mission is to provide high-value, cutting-edge solutions that foster scientific innovation and have a positive impact on human health. The company's approach and product offerings are designed to assist scientists in accelerating discoveries and translating them into clinical development, drug discovery, and basic research.

Dr. Alan Fletcher, Revvity's senior vice president, speaks strongly about the company's commitment. He states that their central goal is to power innovation from research to reality. Revvity serves as a scientific partner for preclinical research and development, GMP manufacturing, global genomic labs, and leading clinical diagnostics.

Advertisment

Highlights at SLAS2024

At SLAS2024, Revvity will be showcasing a variety of its innovative products and services. These will include advancements in cellular research, multiomics, precision medicine, diagnostics, assay development, and automation. The company will also be introducing a new solution for Adeno-associated virus (AAV) analysis aimed at streamlining gene therapy development and manufacturing.

Throughout the exhibit, attendees will have the opportunity to explore the latest product introductions and technological synergies across Revvity's portfolio. These will be featured in several talks and poster presentations spotlighting the company's ongoing work and future plans.

Advertisment

Revvity's Financial Overview

Despite a decrease in revenue and earnings in 2022, Revvity continues to be a buy rating for analysts. Its 12-month stock price forecast is at an increase of 12.58% from the latest price. In the fourth quarter of 2023, the company declared a regular quarterly dividend of $0.07 per share of common stock.

Revvity's board of directors recently welcomed Sophie Vandebroek and Michael Klobuchar. The company is set to release its fourth quarter and full year 2023 financial results on Thursday, February 1, 2024, before the market opens.

Advertisment

Furthering Sustainable Practices

Going beyond its scientific contributions, Revvity has also made strides in promoting sustainability. The company unveiled its inaugural 2023 Environmental, Social and Governance (ESG) Report, emphasizing its commitment to responsible business practices. It also announced a strategic relationship with Scitara and launched the Fontus™ Automated Liquid Handling Workstation, a next-generation liquid handler incorporating the best technology.

In conclusion, Revvity, Inc. is a company committed to driving scientific innovation while making a positive impact on human health. The upcoming SLAS2024 event promises to be an exciting showcase of the company's new branding and innovative solutions.

Advertisment
Chat with Dr. Medriva !